Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|HER2/Neu Negative|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Palbociclib|DRUG: Letrozole|DRUG: Fulvestrant|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment
Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)